Col

TITRE	(EN) Image Guided Intensity Modulated External Beam Radiochemotherapy and MRI Based Adaptive BRAchytherapy in Locally Advanced CErvical Cancer
PROTOCOLE ID	EMBRACE 2
CLINICAL TRIAL.gov ID	NCT03617133
TYPE(S) DE CANCER	Col
PHASE	Phase II
TYPE D'ÉTUDE	Traitement
INSTITUTION	CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL 5415 boul. de l'Assomption (514) 252-3400
VILLE	Montréal
INVESTIGATEUR(RICE) PRINCIPAL(E)	Israël Fortin
COORDONATEUR(RICE)	Véronique Tran veronique.tran.cemtl@ssss.gouv.qc.ca 514-252-3400 poste 3227
STATUT	Actif en recrutement
CRITÈRES D'ÉLIGIBILITÉ	(EN) Cancer of the uterine cervix considered suitable for curative treatment with definitive radio-(chemo)therapy including MRI guided BT Positive biopsy showing squamous-cell carcinoma, adenocarcinoma or adeno-squamous cell carcinoma of the uterine cervix. Staging according to FIGO and TNM guidelines MRI of pelvis at diagnosis is performed MRI, CT or PET-CT of the retroperitoneal space and abdomen at diagnosis is performed MRI with the applicator in place at the time of (first) BT will be performed Para-aortic metastatic nodes below L1-L2 are allowed Patient informed consent
CRITÈRES D'EXCLUSION	(EN) Other primary malignancies except carcinoma in situ of the cervix and basal cell carcinoma of the skin Small cell neuroendocrine cancer, melanoma and other rare cancers in the cervix Metastatic disease above and beyond the retroperitoneal para-aortic L1-L2 interspace Previous pelvic or abdominal radiotherapy Previous total or partial hysterectomy Combination of preoperative radiotherapy with surgery Patients receiving BT only Patients receiving EBRT only Patients receiving neo-adjuvant chemotherapy or other forms of antineoplastic treatment apart from weekly concomitant cisplatin (40 mg/2). However, adjuvant chemotherapy in the form of 4 courses of 3 weekly Carboplatin (AUC 5) and Paclitaxel (155 mg/m2) is allowed according to departmental policy. Contra indications to MRI Contra indications to BT